Biotech News
Related news
HUMAHumacyte2026-11-09 13:00 EST
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
HUMAHumacyte2026-11-10 12:00 EST
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
Humacyte
Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...
Recent company news
HUMAHumacyte2026-11-19 13:00 EST
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
HUMAHumacyte2026-11-16 13:00 EST
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
HUMAHumacyte2026-11-11 13:00 EST
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
HUMAHumacyte2026-11-10 12:00 EST
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
HUMAHumacyte2026-11-09 13:00 EST
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
Stock data
- Close
- 0.54 USD
- Market cap
- 308.61M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
